Search details
1.
High-throughput mapping of the phage resistance landscape in E. coli.
PLoS Biol
; 18(10): e3000877, 2020 10.
Article
in English
| MEDLINE | ID: mdl-33048924
2.
The genetic basis of phage susceptibility, cross-resistance and host-range in Salmonella.
Microbiology (Reading)
; 167(12)2021 12.
Article
in English
| MEDLINE | ID: mdl-34910616
3.
Pharmacokinetics and Time-Kill Study of Inhaled Antipseudomonal Bacteriophage Therapy in Mice.
Antimicrob Agents Chemother
; 65(1)2020 12 16.
Article
in English
| MEDLINE | ID: mdl-33077657
4.
Development of a broad-spectrum Salmonella phage cocktail containing Viunalike and Jerseylike viruses isolated from Thailand.
Food Microbiol
; 92: 103586, 2020 Dec.
Article
in English
| MEDLINE | ID: mdl-32950171
5.
Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation.
Antimicrob Agents Chemother
; 62(2)2018 02.
Article
in English
| MEDLINE | ID: mdl-29158280
6.
Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections.
Pharm Res
; 33(6): 1486-96, 2016 06.
Article
in English
| MEDLINE | ID: mdl-26928668
7.
Quality and safety requirements for sustainable phage therapy products.
Pharm Res
; 32(7): 2173-9, 2015 Jul.
Article
in English
| MEDLINE | ID: mdl-25585954
8.
A suggested new bacteriophage genus: "Viunalikevirus".
Arch Virol
; 157(10): 2035-46, 2012 Oct.
Article
in English
| MEDLINE | ID: mdl-22707043
9.
Topical liquid formulation of bacteriophages for metered-dose spray delivery.
Eur J Pharm Biopharm
; 177: 1-8, 2022 Aug.
Article
in English
| MEDLINE | ID: mdl-35671913
10.
The effects of different doses of inhaled bacteriophage therapy for Pseudomonas aeruginosa pulmonary infections in mice.
Clin Microbiol Infect
; 28(7): 983-989, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35123053
11.
Characterization of a ViI-like phage specific to Escherichia coli O157:H7.
Virol J
; 8: 430, 2011 Sep 07.
Article
in English
| MEDLINE | ID: mdl-21899740
12.
Phage cocktail powder for Pseudomonas aeruginosa respiratory infections.
Int J Pharm
; 596: 120200, 2021 Mar 01.
Article
in English
| MEDLINE | ID: mdl-33486032
13.
Hydrogel formulations containing non-ionic polymers for topical delivery of bacteriophages.
Int J Pharm
; 605: 120850, 2021 Aug 10.
Article
in English
| MEDLINE | ID: mdl-34216771
14.
Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation-A proof-of-principle study in a P. aeruginosa lung infection model.
Eur J Pharm Biopharm
; 158: 166-171, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-33253892
15.
Occurrence of Salmonella-specific bacteriophages in swine feces collected from commercial farms.
Foodborne Pathog Dis
; 7(7): 851-6, 2010 Jul.
Article
in English
| MEDLINE | ID: mdl-20230290
16.
Storage stability of phage-ciprofloxacin combination powders against Pseudomonas aeruginosa respiratory infections.
Int J Pharm
; 591: 119952, 2020 Dec 15.
Article
in English
| MEDLINE | ID: mdl-33059012
17.
Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization.
Bioeng Transl Med
; 5(2): e10159, 2020 May.
Article
in English
| MEDLINE | ID: mdl-32440564
18.
Phage host range and efficiency of plating.
Methods Mol Biol
; 501: 141-9, 2009.
Article
in English
| MEDLINE | ID: mdl-19066818
19.
Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
Eur J Pharm Biopharm
; 142: 543-552, 2019 Sep.
Article
in English
| MEDLINE | ID: mdl-31398437
20.
Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients.
AAPS J
; 21(3): 49, 2019 04 04.
Article
in English
| MEDLINE | ID: mdl-30949776